Targets › SGSH
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine; next expected readout Jun 2027.
Catalyzes a step in lysosomal heparan sulfate degradation. (UniProt, P51688)
Open in Phaseline: the race on SGSH, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical | UX111 Self-complementary adeno-associated virus serotype 9 (scAAV9) carrying the human SGSH gene | SGSH | Phase 2 | MPS IIIA | Mar 2029 |
| GC Biopharma | GC1130A Recombinant human heparan N-sulfatase (rhHNS) | SGSH | Phase 1 | Sanfilippo Syndrome Type A | Jun 2027 |
Sanfilippo Syndrome Type A (1) MPS IIIA (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.